Cargando…
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity
BACKGROUND: The increased incidence of malignant melanoma in recent decades, along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Novel therapeutic strategies, such as immunotherapy and targeted therapy, are urgently needed for melanoma. In this study,...
Autores principales: | Ding, Baoyue, Wu, Xin, Fan, Wei, Wu, Zhaoyong, Gao, Jing, Zhang, Wei, Ma, Lulu, Xiang, Wang, Zhu, Quangang, Liu, Jiyong, Ding, Xueying, Gao, Shen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181059/ https://www.ncbi.nlm.nih.gov/pubmed/21976975 http://dx.doi.org/10.2147/IJN.S24094 |
Ejemplares similares
-
DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo
por: Ding, Baoyue, et al.
Publicado: (2016) -
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo
por: Wu, Xin, et al.
Publicado: (2014) -
Degradable gene delivery systems based on Pluronics-modified low-molecular-weight polyethylenimine: preparation, characterization, intracellular trafficking, and cellular distribution
por: Fan, Wei, et al.
Publicado: (2012) -
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994) -
Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
por: Wu, Xin, et al.
Publicado: (2011)